LPS Response Is Impaired by Urban Fine Particulate Matter

Natália de Souza Xavier Costa 1,*, Gabriel Ribeiro Júnior 1, Adair Aparecida dos Santos Alemany 1, Luciano Belotti 1, Marcela Frota Cavalcante 2, Susan Ribeiro 3,4, Mariana Matera Veras 1, Esper Georges Kallás 3, Paulo Hilário Nascimento Saldiva 1, Marisa Dolhnikoff 1 and Luiz Fernando Ferraz da Silva 1

Abstract: Fine particulate matter (PM2.5) is a complex mixture of components with diverse chemical and physical characteristics associated with increased respiratory and cardiovascular diseases mortality. Our study aimed to investigate the effects of exposure to concentrated PM2.5 on LPS-induced lung injury onset. BALB/c male mice were exposed to either filtered air or ambient fine PM2.5 in an ambient particle concentrator for 5 weeks. Then, an acute lung injury was induced with nebulized LPS. The animals were euthanized 24 h after the nebulization to either LPS or saline. Inflammatory cells and cytokines (IL-1β, IL-4, IL-5, IL-6, IL-10, IL-17, TNF) were assessed in the blood, bronchoalveolar lavage fluid (BALF), and lung tissue. In addition, lung morphology was assessed by stereological methods. Our results showed that the PM+LPS group showed histological evidence of injury, leukocytosis with increased neutrophils and macrophages, and a mixed inflammatory response profile, with increased KC, IL-6, IL-1β, IL-4, and IL-17. Our analysis shows that there is an interaction between the LPS nebulization and PM2.5 exposure, differently modulating the inflammatory response, with a distinct response pattern as compared to LPS or PM2.5 exposure alone. Further studies are required to explain the mechanism of immune modulation caused by PM2.5 exposure.

Keywords: air pollution; acute lung injury; lipopolysaccharides; inflammatory response

1. Introduction

The burden of diseases associated with urban air pollution exposure is large; it especially increases morbidity and mortality from non-communicable cardiovascular and respiratory diseases [1]. Particulate matter (PM) is a complex mixture with diverse chemical and physical characteristic components. To date, strong evidence shows a correlation between fine PM2.5 (particulate matter with an aerodynamic diameter <2.5 μm) exposure and all-cause mortality, such as acute lower respiratory infections, chronic obstructive pulmonary disease, ischemic heart disease, lung cancer, and stroke [2].

The literature abounds with studies showing the effects of individuals chronically exposed to air pollution on their lung health. In humans, chronic exposure to air pollution is associated with decreased lung function [3], increased risk of developing acute respiratory distress syndrome [4], chronic asthma, and pulmonary insufficiency [5], and inflammation has been implicated as the key mechanism of PM-mediated health problems. In addition, PM2.5 exposure can modulate different inflammatory pathways causing a Th1/Th2 and Th17/Treg imbalance [6,7].
The lipopolysaccharide (LPS) is the most abundant component of the Gram-negative bacteria outer membrane and it is composed of a hydrophilic polysaccharide and a highly conserved hydrophobic component referred to as lipid A, which is responsible for the major bioactivity of endotoxin and is recognized by the host immune cells [8]. The asymmetric distribution of the LPS on the surface of the outer membrane is an effective barrier against small, hydrophobic molecules, including many antibiotics [9]. Rapid growth and cell division depend on the bacteria’s capacity to synthesize and export LPS efficiently and in large amounts [10].

LPS also plays a crucial role in bacteria–host interactions by modulating responses by the host immune system, triggering a macrophage-mediated inflammation. Nevertheless, exposure to repeated doses of LPS can lead to tolerance. The LPS tolerance has been described in several species, including humans, suggesting that tolerance may be a protective adaptation to LPS exposure [11].

Previous studies with animal models of LPS-induced acute lung injury and exposure to different types of PM$_{2.5}$ showed aggravation of LPS-related lung injury, neutrophil recruitment, increased oxidative stress, and expression of pro-inflammatory cytokines [12,13]. In most of these experimental studies, the PM$_{2.5}$ exposure is either concomitant with the LPS exposure or only a few days before the LPS instillation [14]. The effects of chronic exposure to PM$_{2.5}$ on the onset and progression of LPS-induced injury are not known. Therefore, this study aims to evaluate how the sub-chronic exposure to PM$_{2.5}$ can alter the inflammatory response of the LPS-induced acute lung injury onset. To our knowledge, this is the first study to assess in vivo the effects of a sub-chronic exposure to “real-world” PM$_{2.5}$ followed by an LPS challenge.

2. Results

2.1. Exposure and PM$_{2.5}$ Characterization

According to Andrade et al. [15] and de Miranda et al. [16], the air pollution at the exposure site was predominantly characterized as emission from vehicular sources. The exposure took place during the dry season and the mean temperature and humidity during the exposure period were 24.3 °C and 55.8%, respectively. The mean PM$_{2.5}$ dose was $1219.1 \pm 616.7 \, \mu g \, m^{-3}$ and the associated 24 h mean PM$_{2.5}$ exposure was $50.8 \, \mu g \, m^{-3}$.

Characterization of the PM$_{2.5}$ collected in filters was previously reported elsewhere. Lopes et al. [17] reported the concentration of PM$_{2.5}$, its black carbon (BC), and metal trace content from the collected filters. Yoshizaki et al. [18] reported the polycyclic aromatic hydrocarbon content, and Costa et al. [19] reported the endotoxin content.

2.2. Histopathological Description

The histopathological evaluation of the lung tissue showed that the control group had a normal appearance, with no significant inflammation nor septal thickening (Figure 1A,B). The PM group presented inflammatory infiltrate alongside the bronchovascular bundle and mild infiltration of inflammatory cells in the alveolar space, with a predominance of mononuclear cells (Figure 1C,D). The LPS group showed important inflammatory infiltrate in the alveolar space and adjacent to the airways and blood vessels, with a predominance of polymorphonuclear cells. There was also septal thickening, alveolar air spaces widening with an irregular distribution, and focal areas of alveolar hemorrhage (Figure 1E,F). In the PM+LPS group, the lung tissue presented perivascular and peribronchial inflammatory infiltrates, presence of inflammatory cells in the alveolar space, septal thickening, and alveolar air spaces widening with an irregular distribution (Figure 1G,H). The semi-quantitative analysis showed a significant increase in the peribronchial inflammation score in the LPS and PM+LPS groups compared to the control ($p \leq 0.0001$ and $p = 0.001$, respectively) and PM ($p = 0.01$ and $p = 0.03$) groups. The alveolar inflammatory infiltrate score was also higher in the LPS group compared to the control ($p = 0.001$) and PM ($p = 0.001$) groups and tended to be higher in the PM+LPS group compared to the control ($p = 0.06$) and PM ($p = 0.06$) groups. The peribronchial inflammation score and alveolar inflammatory...
infiltrate score were both influenced by LPS nebulization \( (p \leq 0.0001, \text{ for both variables}) \) (Table 1).

**Figure 1.** Representative photomicrographs of lung tissue (H&E staining). Control group: (A) 10× and (B) 20×, thin alveolar septa and no significant inflammation. PM group: (C) 10× and (D) 20×, inflammatory infiltrate alongside the bronchovascular bundle and mild presence of inflammatory cells in the alveolar space. LPS group: (E) 10× and (F) 20×, septal thickening and intense inflammatory infiltrate in the alveolar space and adjacent to the airways and blood vessels, with a predominance of polymorphonuclear cells. PM+LPS group: (G) 10× and (H) 20×, septal thickening, peri-airway fibrosis, and dense inflammatory infiltrate.
inflammatory infiltrate alongside the bronchovascular bundle and mild presence of inflammatory cells in the alveolar space. LPS group: (E) $10 \times$ and (F) $20 \times$, septal thickening and intense inflammatory infiltrate in the alveolar space and adjacent to the airways and blood vessels, with a predominance of polymorphonuclear cells. PM+LPS group: (G) $10 \times$ and (H) $20 \times$, septal thickening, perivascular and peribronchial inflammatory infiltrates, and presence of inflammatory cells in the alveolar space. AW: Airway. BV: Blood Vessel. Green Arrowhead: inflammatory cell infiltration in the peribronchial and perivascular areas. Blue Arrowhead: interalveolar inflammatory cells. $10 \times$: scale bar = 100 $\mu$m and $20 \times$: scale bar = 50 $\mu$m.

Table 1. Semi-quantitative analysis of the inflammation and stereological assessment of the lung tissue.

| Parameter                                      | Control | PM     | LPS    | PM+LPS | LPS Nebulization | PM2.5 Exposure | Interaction |
|------------------------------------------------|---------|--------|--------|--------|------------------|----------------|-------------|
| Initial Body Weight (g)                        | 22 (3)  | 23 (2) | 22 (2) | 24 (4) | ns               | ns             | ns          |
| Final Body weight (g)                          | 24 (2) $^b$ | 26.5 (3.5) $^b$ | 21.5 (2) | 20 (4) | $p \leq 0.0001$ | ns             | $p = 0.042$ |
| Peribronchial inflammation score               | 0 (1) $^b$ | 1 (1) $^b$ | 1.5 (1) | 1.5 (1) | $p \leq 0.0001$ | ns             | ns          |
| Alveolar inflammatory infiltrate score         | 0 (1) $^b$ | 0 (1) $^b$ | 2 (1)  | 1 (1)  | $p \leq 0.0001$ | ns             | ns          |
| Lung volume (mm$^3$)                           | 431.2 (145) | 486.1 (172) | 462.6 (55) | 470.4 (94) | ns               | ns             | ns          |
| Lung volume per body weight ratio (mm$^3$/g)   | 18.8 (4.7) | 17.5 (8.4) | 20.9 (3.3) | 22.7 (3) $^a$ | $p = 0.02$ | ns             | ns          |
| Vv parenchyma (%)                              | 78.1 (10) | 78.5 (6) | 81.6 (8) | 77.6 (8) | ns               | ns             | ns          |
| Vv septa (%)                                   | 28.8 (7.4) | 32.8 (4.7) | 34.3 (3.3) | 34.5 (7.7) $^a$ | $p = 0.031$ | ns             | ns          |
| Vv alveolar airspace (%)                       | 49.3 (2.6) | 46.9 (5.8) $^c$ | 48.6 (6.1) | 44.3 (5.8) | $p = 0.01$ | ns             | ns          |
| Vv non-parenchyma (%)                          | 21.9 (15) | 21.5 (6) | 18.4 (8) | 22.4 (8) | ns               | ns             | ns          |
| Vt parenchyma (mm$^3$)                         | 332.9 (116.8) | 392.2 (162.6) | 368.4 (48.8) | 369.2 (50.9) | ns               | ns             | ns          |
| Vt septa (mm$^3$)                              | 125.4 (31.2) | 163.5 (61.1) $^a$ | 181.7 (35.2) | 129.9 (70.9) | ns               | ns             | ns          |
| Vt alveolar airspace (mm$^3$)                  | 199.4 (73.9) | 230.2 (110) $^c$ | 264.9 (71.7) | 183.6 (63.2) | ns               | ns             | $p = 0.004$ |
| Vt non-parenchyma (mm$^3$)                     | 80.4 (65.5) | 105.9 (47.9) | 76.5 (40.15) | 102 (41.3) | ns               | ns             | ns          |
| Sv septa (mm$^-1$)                             | 238.9 (53.6) | 211 (47.1) | 199.8 (27.8) $^a$ | 204.1 (16.9) $^a$ | $p = 0.01$ | ns             | ns          |
| St septa (10$^2$ mm$^2$)                       | 94.6 (36.9) | 113.1 (52) | 89.8 (23.9) | 92.8 (23.6) | ns               | ns             | ns          |
| Septal thickness (µm)                          | 2.6 (1) | 3.1 (1.2) | 3.7 (1.3) $^a$ | 3.3 (1.7) $^a$ | $p = 0.004$ | ns             | ns          |

Data are expressed in median (interquartile range). ns: not significant. $^a$ $p > 0.05$ compared to the control group. $^b$ $p > 0.05$ compared to the LPS group. $^c$ $p > 0.05$ compared to the PM+LPS.

2.3. Stereological Analysis

The body weight at the beginning of the exposure period was not different among the groups. The final body weight was decreased in the LPS and PM+LPS groups compared to the control ($p = 0.022$ and $p = 0.008$, respectively) and PM ($p \leq 0.0001$ and $p \leq 0.0001$, respectively) groups. The two-way ANOVA analyses showed that the body weight was influenced by the LPS nebulization ($p \leq 0.0001$). The total lung volume was not statistically different among the groups. The lung volume per body weight ratio was increased in the PM+LPS group compared to the control ($p = 0.04$), also influenced by the LPS nebulization ($p = 0.02$).

The volumetric density and total volume of the lung parenchyma were not different among the groups. The septa volume density was increased in the PM+LPS group compared to the control ($p = 0.049$), due to the LPS nebulization ($p = 0.031$), and the alveolar airspace volume density was decreased in the PM+LPS group compared to the LPS group ($p = 0.049$), as a consequence of the PM$_{2.5}$ exposure ($p = 0.01$). Furthermore, the total septa volume was increased in the LPS group compared to the control ($p = 0.024$) group and the
alveolar total volume was decreased in the PM+LPS group compared to the LPS \((p = 0.02)\) group, both due to the interaction between LPS nebulization and PM\(_{2.5}\) exposure \((p = 0.002\) and \(p = 0.004\), respectively).

The volume density and total volume of the non-parenchyma structures were not different among the groups.

The septa surface density was decreased in the LPS \((p = 0.035)\) and PM+LPS \((p = 0.018)\) groups compared to the control due to the LPS nebulization \((p = 0.01)\); however, there was no difference in the septa total surface area among the groups.

The septum arithmetic mean thickness was increased in the LPS \((p = 0.018)\) and PM+LPS \((p = 0.023)\) groups compared to the control, influenced by the LPS nebulization \((p = 0.004)\).

All the stereological data are summarized in Table 1.

### 2.4. Inflammatory Cells Assessment

The data from the red blood cell count, fibrinogen, and platelet quantification are presented in Supplementary Table S1.

The circulating leukocytes were increased in the PM group compared to the control \((p = 0.012)\) and PM+LPS \((p = 0.003)\) groups, as a result of the interaction between the LPS nebulization and PM\(_{2.5}\) exposure \((p \leq 0.0001)\). The BALF leukocytes were increased in the LPS group compared to the control \((p \leq 0.0001)\) and PM \((p = 0.002)\) groups. It was also increased in the PM+LPS group compared to the control \((p = 0.005)\) group. The BALF leukocytes outcome was influenced by the LPS nebulization \((p \leq 0.0001)\) and by the interaction between the LPS nebulization and PM\(_{2.5}\) exposure \((p = 0.003)\) (Figure 2).

The circulating neutrophils were increased in the LPS group compared to the control \((p = 0.001)\) and PM+LPS \((p = 0.002)\) group. In addition, the PM group also displayed increased neutrophils compared to the control \((p = 0.03)\) and PM+LPS \((p = 0.039)\) groups, influenced by the interaction between the LPS nebulization and PM\(_{2.5}\) exposure \((p \leq 0.0001)\). The BALF neutrophils were increased in the LPS and PM+LPS groups compared to both the control \((p \leq 0.0001)\) and PM \((p \leq 0.0001)\) and PM+LPS \((p \leq 0.0001)\), respectively) groups, because of the LPS nebulization \((p \leq 0.0001)\), PM\(_{2.5}\) exposure \((p \leq 0.0001)\), and their interaction \((p \leq 0.0001)\). MPO+ neutrophils, assessed in the lung parenchyma, were increased in the LPS group compared to the control \((p \leq 0.0001)\), PM \((p \leq 0.0001)\), and PM+LPS \((p \leq 0.0001)\) groups, also influenced by the LPS nebulization \((p \leq 0.0001)\), PM\(_{2.5}\) exposure \((p \leq 0.0001)\), and their interaction \((p \leq 0.0001)\) (Figure 2).

The circulating lymphocytes were increased in the PM group compared to the control \((p = 0.011)\), LPS \((p = 0.01)\), and PM+LPS \((p = 0.001)\) groups, as a consequence of the PM\(_{2.5}\) exposure \((p = 0.005)\). The BALF lymphocytes were not different between the groups. The proportion of CD3+ lymphocytes in the lung parenchyma was increased in the LPS group compared to the control \((p = 0.001)\), PM \((p \leq 0.0001)\), and PM+LPS \((p = 0.028)\) groups, influenced by LPS nebulization \((p \leq 0.0001)\) and PM\(_{2.5}\) exposure \((p = 0.009)\) (Figure 2).

There was no statistical difference in the circulating monocytes among the groups. The BALF macrophages were decreased in the LPS and PM+LPS groups compared to the control \((p = 0.004\) and \(p = 0.014\), respectively) and PM \((p = 0.001\) and \(p = 0.003\), respectively) groups, as a result of the LPS nebulization \((p \leq 0.0001)\). The proportion of MAC2+ macrophages present in the lung parenchyma was increased in the LPS \((p = 0.008)\), PM \((p = 0.009)\), and PM+LPS \((p = 0.017)\) groups compared to the control group, influenced by the LPS nebulization \((p = 0.026)\), PM\(_{2.5}\) exposure \((p = 0.043)\), and their interaction \((p = 0.011)\).

The Foxp3 mRNA expression was higher in the LPS group compared to the control \((p = 0.001)\) and PM+LPS \((p = 0.001)\). Moreover, the PM group tended to increase compared to the PM+LPS group \((p = 0.06)\). The two-way ANOVA showed an interaction between the LPS nebulization and the PM\(_{2.5}\) exposure \((p \leq 0.0001)\) (Figure 3).
Figure 2. Graphical representation of inflammatory cells assessed in the blood (10³ cells/mm³), BALF (10⁴ cells/mL), and lung parenchyma (10⁻⁵ cells/µm²). Each point represents one animal and bars show the median. * \( p < 0.05 \) compared to the control group. ‡ \( p < 0.05 \) compared to the LPS group. ∆ \( p < 0.05 \) compared to the PM group. # \( p < 0.05 \) compared to the PM+LPS group.

2.5. Inflammatory Cytokines

Besides the different inflammatory profiles that were analyzed in the blood serum, BALF, and lung parenchyma, we also analyzed the mRNA expression of the TLR-2, TLR-4, and MyD-88. All data from the inflammatory cytokines assessment are presented in Table 2.

The mRNA expression of the TLR-2 was not different among the groups (Figure 3). The mRNA expression of the TLR-4 was higher in the LPS group compared to the control \( (p \leq 0.0001) \), PM \( (p \leq 0.0001) \), and PM+LPS \( (p \leq 0.0001) \) group (Figure 3). Following the same pattern, the mRNA expression of MyD-88 was also higher compared to the control \( (p \leq 0.0001) \), PM \( (p \leq 0.0001) \), and PM+LPS \( (p \leq 0.0001) \) groups (Figure 3). The two-way ANOVA analysis showed that the results from the TLR-4 and MyD-88 assessments were influenced by the LPS nebulization \( (p \leq 0.0001 \text{ for both variables}) \), PM\(_{2.5}\) exposure \( (p \leq 0.0001 \text{ and } p = 0.001, \text{ respectively}) \), and by their interaction \( (p \leq 0.0001 \text{ for both variables}) \).

The group LPS had higher levels of KC in the blood serum compared to the control \( (p \leq 0.0001) \), PM \( (p \leq 0.0001) \), and PM+LPS \( (p = 0.003) \), these results were influenced by the LPS nebulization \( (p \leq 0.0001) \), PM\(_{2.5}\) exposure \( (p = 0.007) \), and their interaction \( (p = 0.013) \). Moreover, in the BALF, the group LPS also had higher levels of KC compared to the control \( (p \leq 0.0001) \), PM \( (p \leq 0.0001) \), and PM+LPS \( (p = 0.017) \) groups. The PM+LPS group had increased KC levels in the BALF compared to the control \( (p \leq 0.0001) \) and PM \( (p \leq 0.0001) \)
groups. The results in the BALF were also influenced by the LPS nebulization \( (p \leq 0.0001) \), PM\(_{2.5}\) exposure \( (p = 0.03) \), and their interaction \( (p = 0.018) \).

![Graphical representation of mRNA expression](image)

**Figure 3.** Graphical representation of (A) relative TLR-4 mRNA expression, (B) relative TLR-2 mRNA expression, (C) relative MyD-88 mRNA expression, and (D) relative FOXP3 mRNA expression assessed in the lung tissue. Each point represents one animal and bars show the median. ‡ *p* < 0.05 compared to the LPS group.

**Table 2.** Inflammatory cytokines.

|                  | Control     | PM         | LPS        | PM+LPS     | LPS Nebulization | PM\(_{2.5}\) Exposure | Interaction |
|------------------|-------------|------------|------------|------------|------------------|------------------------|-------------|
| **KC** Serum (pg/mL) | 3.8 (1.3)\(^b\) | 3.7 (2.4)\(^b\) | 16.8 (9.7) | 7.5 (3)\(^b\) | \( p \leq 0.0001 \) | \( p = 0.007 \) | \( p = 0.013 \) |
|                  | BALF (pg/mL) | 0.6 (2.5)\(^bd\) | 0.9 (5.7)\(^bd\) | 103.6 (24.3) | 60.7 (74.2)\(^b\) | \( p \leq 0.0001 \) | \( p = 0.03 \) | \( p = 0.018 \) |
| **IL-1β** Serum (pg/mL) | >LD | >LD | 0 (0.04) | >LD | ns | ns | ns |
|                  | BALF (pg/mL) | >LD\(^bc\) | >LD\(^bd\) | 23.7 (15.1) | 12.9 (7.5) | \( p \leq 0.0001 \) | ns | ns |
|                  | Tissue (\(\mu\text{m}^2/\mu\text{m}^2\)) | 0.02 (0.02) | 0.005 (0.005)\(^d\) | 0.03 (0.06) | 0.06 (0.006) | \( p = 0.005 \) | ns | ns |
| **IL-6** Serum (pg/mL) | 0.1 (0.3) | 0.1 (0.2)\(^b\) | 9.3 (7.9) | 7.7 (13.2) | \( p = 0.002 \) | ns | ns |
|                  | BALF (pg/mL) | >LD\(^bd\) | 0.01 (0.3)\(^bd\) | 800.8 (613.5) | 325.3 (231.2)\(^b\) | \( p \leq 0.0001 \) | \( p \leq 0.0001 \) | \( p \leq 0.0001 \) |
|                  | Tissue (\(\mu\text{m}^2/\mu\text{m}^2\)) | 0.01 (0.02)\(^c\) | 0.001 (0.002) | 0.02 (0.02)\(^c\) | 0.01 (0.01)\(^c\) | \( p = 0.035 \) | ns | \( p = 0.044 \) |
Table 2. Cont.

|                       | Control     | PM          | LPS         | PM+LPS      | LPS Nebulization | PM_{2.5} Exposure | Interaction |
|-----------------------|-------------|-------------|-------------|-------------|------------------|-------------------|-------------|
| **TNF**               |             |             |             |             |                  |                   |             |
| Serum (pg/mL)         | 0.8 (1.2) b | 0.9 (1.7) b | 5.1 (3.4)   | 2.3 (0.8) b |                  |                   |             |
|                       |             |             |             |             |                  |                   |             |
| BALF (pg/mL)          | 0.01 (0.4) b| 0.1 (1) b   | 2822.1 (1310.3) | 486.5 (379.8) b |                  | p ≤ 0.0001        | p ≤ 0.0001 |
| Tissue (µm²/µm²²)     | 0.04 (0.07) | 0.04 (0.05) | 0.05 (0.1)  | 0.03 (0.07)  |                  | ns                | ns          |
| **IL-4**              |             |             |             |             |                  |                   |             |
| Serum (pg/mL)         | >LD         | >LD         | >LD         | >LD         |                  | ns                | ns          |
| BALF (pg/mL)          | >LD         | >LD         | >LD         | >LD         |                  | ns                | ns          |
| Tissue (µm²/µm²²)     | 0.08 (0.03) cd | 0.3 (0.1)  | 0.1 (0.06) cd | 0.2 (0.2)  |                  | ns                | p ≤ 0.0001 |
| **IL-5**              |             |             |             |             |                  |                   |             |
| Serum (pg/mL)         | 0.3 (0.5)   | 0.8 (0.8)   | >LD c       | >LD c       | p ≤ 0.0001       | ns                | ns          |
| BALF (pg/mL)          | >LD         | >LD         | >LD         | >LD         |                  | ns                | ns          |
| Tissue (µm²/µm²²)     | 0.05 (0.06) c | 0.02 (0.01) | 0.06 (0.06) c | 0.05 (0.02) |                  | ns                | p = 0.015  |
| **IL-10**             |             |             |             |             |                  |                   |             |
| Serum (pg/mL)         | 0.4 (1.5)   | 0.1 (0.7)   | 1.1 (2.3)   | 0 (0.1)     |                  | ns                | ns          |
| BALF (pg/mL)          | 0 (0.9)     | 0 (0.3)     | 1.1 (2.9)   | 0 (0.4)     |                  | ns                | ns          |
| Tissue (µm²/µm²²)     | 0.015 (0.02) | 0.003 (0.008) b | 0.035 (0.08) | 0.007 (0.01) b | p = 0.04         | p = 0.001         |             |
| **IL-17A**            |             |             |             |             |                  |                   |             |
| Serum (pg/mL)         | 1.7 (0.4)   | 1.8 (0.4)   | 1.5 (0.5)   | 1.6 (0.1)   |                  | ns                | ns          |
| BALF (pg/mL)          | 1.2 (0.1) b | 1.2 (0.2) b | 6.5 (9.3)   | 3.9 (3.1)   | p = 0.009        | ns                | ns          |
| Tissue (µm²/µm²²)     | 0.01 (0.01) c | 0.1 (0.08) c | 0.03 (0.01) | 0.04 (0.03) c | ns                | p ≤ 0.0001        | p = 0.04   |

Data are expressed in median (interquartile range). >LD, below the limit of detection. ns, not significant. a p > 0.05 compared to the control group. b p > 0.05 compared to the LPS group. c p > 0.05 compared to the PM. d p > 0.05 compared to the PM+LPS.

There was no difference in the IL-1beta levels detected in the blood serum. In the BALF, the levels of IL-1beta were higher in the LPS group compared to the control (p ≤ 0.0001), PM (p ≤ 0.0001), and a tendency towards increase compared to the PM+LPS group (p = 0.06) was observed. In addition, the levels of IL-1beta were also higher in the PM+LPS group compared to the control (p = 0.001) and PM (p = 0.002) groups, as a result of the LPS nebulization (p ≤ 0.0001). In the lung parenchyma, the proportion of IL-1beta was increased in the PM+LPS group compared to the PM (p = 0.026), also due to the LPS nebulization (p = 0.005) (Figure 4).

The serum levels of IL-6 in the LPS group were higher than in the PM group (p = 0.027) and tended to increase compared to the control (p = 0.06), influenced only by the LPS nebulization (p = 0.002). In the BALF, the LPS group had greater levels of IL-6 compared to the control (p ≤ 0.0001), PM (p ≤ 0.0001), and PM+LPS (p ≤ 0.0001) groups. The PM+LPS also had higher levels of IL-6 in the BALF compared to the control (p = 0.008) and PM (p = 0.008) groups. The BALF levels of IL-6 were influenced by the LPS nebulization (p ≤ 0.0001), PM_{2.5} exposure (p ≤ 0.0001), and their interaction (p ≤ 0.0001). In the lung parenchyma, the proportion of IL-6 was decreased in the PM group compared to the control (p = 0.044), LPS (p = 0.03), and PM+LPS (p = 0.027), as a result of the LPS nebulization (p = 0.035) and the interaction between LPS nebulization and PM_{2.5} exposure (p = 0.044) (Figure 4).
The total TNF levels were increased in the LPS group compared to the control ($p = 0.001$), PM ($p = 0.001$), and PM+LPS ($p = 0.009$) groups in the blood serum, as a consequence of the LPS nebulization ($p = 0.001$) and the interaction between LPS nebulization and PM$_{2.5}$ exposure ($p = 0.009$). Following the same pattern, the BALF total TNF levels were higher in the LPS group compared to the control ($p \leq 0.0001$), PM ($p \leq 0.0001$), and PM+LPS ($p \leq 0.0001$), as a result of the LPS nebulization ($p \leq 0.0001$), PM$_{2.5}$ exposure ($p \leq 0.0001$), and their interaction ($p \leq 0.0001$). In the lung parenchyma, the proportion of TNF-alpha had no significant difference among the groups (Figure 4).

The IL-4 levels in the blood serum and BALF had no difference among the groups. In the lung parenchyma, the PM+LPS group had increased IL-4 compared to the control ($p = 0.003$) and LPS ($p = 0.013$) groups. The PM group had even higher levels of IL-4 compared to the control ($p \leq 0.0001$), LPS ($p \leq 0.0001$), and tended to increase compared to the PM+LPS ($p = 0.06$) group. These results were influenced by the PM$_{2.5}$ exposure ($p \leq 0.0001$) and by the interaction between LPS nebulization and PM$_{2.5}$ exposure ($p = 0.027$) (Figure 5).
The blood serum IL-5 levels were lower in the LPS \( (p = 0.004) \) and PM+LPS \( (p = 0.003) \) groups compared to the PM group, influenced by the LPS nebulization \( (p \leq 0.0001) \). The levels of IL-5 were below the limit of detection in the BALF samples. In the lung parenchyma, the levels of IL-5 were lower in the PM group compared to the control \( (p = 0.02) \) and LPS \( (p = 0.018) \) groups, due to the PM\(_{2.5}\) exposure \( (p = 0.015) \) (Figure 5).

The levels of IL-10 in the blood serum and BALF were not statistically different among the groups. In the lung parenchyma, the IL-10 was increased in the LPS group compared to the PM \( (p = 0.003) \) and PM+LPS \( (p = 0.008) \) groups, as a result of the LPS nebulization \( (p = 0.04) \) and PM\(_{2.5}\) exposure \( (p = 0.001) \) (Figure 5).

There was no statistical difference in the blood serum IL-17 levels among the groups. The LPS groups had higher levels of IL-17 in the BALF compared to the control \( (p = 0.022) \) and PM \( (p = 0.02) \) groups, as a result of the LPS nebulization \( (p = 0.009) \). In the lung parenchyma, the PM group had higher levels of IL-17 compared to the control \( (p \leq 0.0001) \), LPS \( (p = 0.001) \), and PM+LPS \( (p = 0.014) \) groups. The PM+LPS tended to increase compared to the control group \( (p = 0.06) \). The IL-17 levels in the lung parenchyma were influenced by PM\(_{2.5}\) exposure \( (p \leq 0.0001) \) and by the interaction between LPS nebulization and PM\(_{2.5}\) exposure \( (p = 0.004) \) (Figure 6).
of IL-5 in the lung parenchyma. Representative photomicrographs of the lung parenchyma immunostained with anti-IL-5 antibody: (G) control group, (H) PM group, (I) LPS group, and (J) PM+LPS group. Positive stains for IL-5 are mostly in the epithelial cells. (K) Graphical representation of IL-10 in the lung parenchyma. Representative photomicrographs of the lung parenchyma immunostained with anti-IL-10 antibody: (L) control group, (M) PM group, (N) LPS group, and (O) PM+LPS group. In the LPS group, positive stains for IL-10 are mostly in the inflammatory cells. Each point of the graph represents one animal and bars show the median. ‡ p < 0.05 compared to the LPS group. ∆ p < 0.05 compared to the PM group. # p < 0.05 compared to the PM+LPS group. Scale bars = 50 μm.

Figure 6. Graphical representation of IL-17 assessment in the lung parenchyma and representative photomicrographs of immunostained lung tissue. (A) Graphical representation of IL-17 in the lung parenchyma. Representative photomicrographs of the lung parenchyma immunostained with anti-IL-17 antibody: (B) control group, (C) PM group, (D) LPS group, and (E) PM+LPS group. The IL-17 staining has a different pattern in each group. The PM group exhibits intense positive stains for IL-17 mostly in the epithelial cells. The LPS group exhibits positive stains for IL-17 mostly in the inflammatory. The PM+LPS group also exhibits intense positive stains for IL-17 mostly in the epithelial cells, however with a very irregular distribution, staining mainly the alveolar ducts. Each point of the graph represents one animal and bars show the median. ∆ p < 0.05 compared to the PM group. Scale bars = 50 μm.

3. Discussion

Exposure to air pollution is a risk factor for respiratory and cardiovascular non-communicable diseases and the fine particulate matter, which can reach the deepest parts of the lungs, can regulate several inflammatory pathways, cytokines, and genes leading to an inflammation-related injury [1,6]. Our study suggests that sub-chronic exposure to fine particulate matter can alter the inflammatory response induced by LPS. Like the LPS group,
the PM+LPS group showed histological evidence of injury and septal thickening, increased BALF leukocytes and neutrophils, increased macrophages in the lung tissue, increased levels of KC and IL-6 in the BALF, and increased levels of IL-1β in the BALF and lung parenchyma. However, unlike the LPS group, it did not show changes in MPO+ neutrophils and CD3+ lymphocytes in the lung parenchyma, in the levels of TNF or IL-10, or in the expression of TLR-4 and MyD-88. Moreover, like the PM group, the PM+LPS group had increased levels of IL-4 and IL-17 in the lung parenchyma, but unlike the PM group, it did not show changes in the expression of FOXP3 in the lung tissue. It is worth noting that, although not always statistically different, all increased cytokines in the PM+LPS group (KC, IL-6, IL-1β, IL-4, and IL-17) are not as increased as in the reference group (LPS or PM group).

LPS is a potent microbial inducer of inflammation and its inflammatory response in the lungs is characterized by the polymorphonuclear influx, high levels of MPO, and increased pro-inflammatory cytokines in the BALF [20]. The LPS group showed the expected inflammatory response to the LPS exposure. Besides the histological evidence of tissue injury and septal thickening, the LPS group also showed increased BALF leukocytes, increased neutrophils in the blood, BALF, and lung parenchyma, and increased lung tissue T-lymphocytes. Furthermore, the LPS group also showed higher levels of the pro-inflammatory cytokines KC, IL-6, and TNF in blood serum and BALF; increased IL-1 beta and IL-17 in the BALF, and increased mRNA expression of FOXP3, TLR4, and MyD88. The role of the TLR-4 and MyD88 in LPS-induced inflammation is well described in the literature [21]. Our results showed that the LPS group had increased mRNA expression of TLR-4 and MyD-88, whereas the group PM+LPS did not display this pattern. Even though we did not measure the protein expression of TLR-4 and MyD-88, the changes in their mRNA expression may indicate that they may play a role in the process.

The recognition of LPS by the immune system is an important first step in identifying invading pathogens and in initiating a protective immune response; therefore, any impairment in this process can potentially increase the susceptibility to certain infectious agents. It has been reported that exposure to air pollution increases the susceptibility to infections caused by bacteria, such as *Pseudomonas aeruginosa* [22], *Streptococcus pneumoniae* [23], and *Mycobacterium tuberculosis* [24]. In addition, there is also an association between exposure to air pollution and the transmission/severity of viral infections [25].

The PM group displayed a very different inflammatory pattern from the LPS group, with the increase in circulating leukocytes and lymphocytes, increased BALF and lung parenchyma macrophages, increased levels of IL-5 in the blood serum, and increased levels of IL-4 and IL-17 in the lung parenchyma. Many studies have shown the connection between the concentration of PM$_{2.5}$ and the development or exacerbation of allergies and inflammatory/autoimmune disorders [7].

Previous studies suggest that exposure to PM$_{2.5}$ can impair the macrophages’ phagocytosis [26] and pathogen opsonization, decrease antigen presentation [27,28], and disturb the Th1/Th2 balance, switching to a Th2-dominant profile, mainly via the presence of PAHs in the PM$_{2.5}$ [6]. In addition, when relatively low levels of LPS are inhaled, a cascade of immune responses leads to Th2 cells differentiation, activation of dendritic cells, and the increase in IL-4, IL-5, and IL-13 [29].

IL-17A is a cytokine that acts as part of the host defense to bacterial and fungal infections and aberrant IL-17 signaling can lead to excess inflammation [30]. Previous studies showed that exposure to air pollution increases the levels of IL-17 and enhances Th17 differentiation through the aryl hydrocarbon receptor (AHR) [31,32]. Moreover, Gałuszka et al. [7] reported that T cells exposed to transition metal-containing particulate matter showed an increase in the proportion of IFN-γ and IL-17A producing cells, with a concomitant decrease in Treg cells. Our results suggest a Th17/Treg imbalance in our animal exposed to PM$_{2.5}$ with increased expression of IL-17 in the lung parenchyma and decreased expression of Foxp3 mRNA. Although the Foxp3 mRNA expression may not exclusively represent Tregs, there is evidence that mRNA expression and immunostained Foxp3 cells
are correlated [33]. In addition, Nadeau et al. [34] showed that PM$_{2.5}$ suppresses Treg through its ability in causing hypermethylation of the gene encoding the Treg-transcription factor (Foxp3) in the peripheral blood of children with asthma.

The organic compounds present in the PM$_{2.5}$, such as pollen, fungal spores, mold, and microbial components (including LPS) also play an important role in inflammation modulation [6] and, we have confirmed the presence of LPS in the PM$_{2.5}$ that the animals were exposed [19]. Nomura et al. [35] showed that macrophages exposed to low levels of LPS show reduced response to a second stimulation with LPS by downregulating TLR4 leading to a time- and dose-dependent reduction in the production of inflammatory cytokines. This LPS tolerance compromises the ability of macrophages to mount an effective immune response during a subsequent pathogen encounter [36]. A growing body of evidence suggests that the effects of air pollution exposure on the pathogenesis of respiratory infections may be pollutant-, timing-, and infection-specific [37].

Air pollution is a great environmental risk to health and PM$_{2.5}$ exposure is the fifth leading risk factor for death in the world, accounting for 4.2 million deaths [1]. The Metropolitan Area of São Paulo is a megacity with a population of 21 million, corresponding to more than 11% of the total population of Brazil [38]. The São Paulo State (Brazil) air quality standards recommend that the 24 h mean PM$_{2.5}$ concentration should not exceed 60 µg·m$^{-3}$ [39], which is fourfold higher than the new 24 h mean level of 15 µg·m$^{-3}$ recommended by the World Health Organization [2]. According to the São Paulo State air quality standard classification, the 24 h mean of 50.8 µg·m$^{-3}$ would be in the range between moderate and bad air quality. From 2016 to 2020, the annual percentage distribution of days that had moderate air quality or worse in the monitoring stations ranged from 13.8 to 16.3% [39].

Research on PM$_{2.5}$ and the interpretation of research findings on exposure and risk are complicated by this heterogeneity and the possibility that the potential of particles to cause injury varies with size and other physical characteristics, chemical composition, and source(s) [2].

All the employed methodology in this study was selected taking into account the availability of our materials and resources. One of the strengths of our study is the PM$_{2.5}$ exposure method. The ambient particle concentrator mimics human whole-body exposure, concentrating the “real world” particles with no need of sedation and minimum impact on mice’s food intake and drinking during the exposure. Animal models are an important tool to test hypotheses offering controlled conditions and generating reproducible results; however, several limitations should be considered when investigating the effects of inhaled PM$_{2.5}$. There are considerable differences between the human and mouse respiratory system anatomy and immunology. To cite a few examples: mice have complex nasal anatomy, a lower number of cilia, fewer club cells, differences in pulmonary lobulation, bronchial branching, and a lack of respiratory bronchioles, all features that can affect particle retention and distribution [40]. In addition, mice differ from humans regarding the balance of leukocyte subsets, Ig subsets, and chemokine and its receptor expression [41]. Even though the translation of the results into humans may be limited, they bring interesting insights for future studies in humans. Furthermore, it is unclear how the different PM$_{2.5}$ components are responsible for the observed effects.

4. Materials and Methods

The Institutional Review Board for Ethics on Animal Use approved all ethics aspects of this project (protocol no. 177/10), including animal manipulation and euthanasia. Moreover, according to the institutional guidelines for animal welfare, all animals were treated with due consideration to the alleviation of distress and discomfort.

4.1. Study Design

We designed this experimental study to investigate the effects of exposure to concentrated PM$_{2.5}$ on LPS-induced lung injury onset. To do so, sixty-four BALB/c male
mice (9 weeks old) were obtained from our university’s animal facility and maintained at 22–26 °C and 55–75% humidity under a 12/12 h dark/light cycle with food and water provided ad libitum.

Animals were exposed to ambient PM$_{2.5}$ in an ambient particle concentrator (APC), described in Sioutas et al. [42], developed at the Harvard School of Public Health. The APC is located close to a high-traffic road (23°33′18.1″ S 46°40′15.0″ W), inside the School of Medicine of São Paulo University campus. Animals were placed inside the exposure chambers with controlled temperature, humidity, and pressure, either connected to the concentrate PM$_{2.5}$ stream (PM and PM+LPS groups) or to a clean air supply provided using a high-efficiency particulate air filter (control and LPS groups). The mass concentrations of PM$_{2.5}$ were measured using an airborne particulate monitor (two-wavelength nephelometer, DataRam DR-4000, Thermo Fisher Scientific, Waltham, MA, USA) during the exposure. During the exposure, the concentration of PM$_{2.5}$ is susceptible to fluctuations; therefore, the time of exposure was adjusted proportionally to the APC-derived PM$_{2.5}$ concentration at the start of each exposure to achieve our target dose of 1200 µg·m$^{-3}$ for 1 h daily, not exceeding the limit of 120 min per day.

The acute lung injury was induced with nebulized LPS (Lipopolysaccharides from Escherichia coli O111:B4—Sigma-Aldrich, St. Louis, MO, USA) at a 3 mg/mL concentration as previously described by Costa et al. [43]. Therefore, four experimental groups were established: 1. Control group—mice exposed to filtered air for 5 weeks and exposed to nebulized saline. 2. PM group—mice exposed to PM$_{2.5}$ (daily dose: 1200 µg·m$^{-3}$) for 5 weeks and exposed to nebulized saline. 3. LPS group—mice exposed to filtered air for 5 weeks and exposed to nebulized LPS. 4. PM+LPS—mice exposed to PM$_{2.5}$ (daily dose: 1200 µg·m$^{-3}$) for 5 weeks and exposed to nebulized LPS.

All animals were euthanized with an intraperitoneal injection of sodium thiopental (200 mg·kg$^{-1}$ body weight) 24 h after the nebulization to either LPS or saline. Blood samples were collected from all animals. From 7–8 animals of each group, samples from one lung were frozen for the molecular analysis and the other lung fixed in 4% buffered paraformaldehyde solution for the histopathological/immunohistochemical evaluation. From the remaining animals ($n = 7–8$ per group), BALF was collected, and both lungs were fixed in 4% buffered paraformaldehyde solution for the stereological analyses.

**4.2. PM$_{2.5}$ Elementary Characterization**

PM$_{2.5}$ was collected in polycarbonate filter membranes. Concentrations of metal trace elements and black carbon (BC) concentration were assessed as previously described by Andrade et al. [15] and de Miranda et al. [16]. The polycyclic aromatic hydrocarbon (PAHs) content of PM$_{2.5}$ was assessed as previously described by Yoshizaki et al. [18]. The endotoxin content in the PM$_{2.5}$ was quantified with the ToxinSensor Chromogenic LAL Endotoxin Assay Kit (GenScript, Piscataway, NJ, USA), as recommended by the manufacturer’s instructions.

**4.3. Blood and Bronchoalveolar Lavage Fluid (BALF) Analysis**

Full and differential cell counts were performed in the total blood and BALF samples. Differential cell counts were performed using the May-Grünwald-Giemsa stain (300 cells per animal). Inflammatory cytokines IL-1β, IL-4, IL-5, IL-6, IL-10, IL-17, KC, and total TNF were quantified by the cytometric bead assay (BD Bioscience, San Jose, CA, USA) according to the manufacturer’s instructions, in the BALF and blood serum. One thousand and two hundred events were acquired by a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA), and data were analyzed with FCAP Array software (BD Biosciences, San Jose, CA, USA).
4.4. Stereological Analysis and Descriptive Analysis

Lung stereology was carried out as described in Hsia et al. [44] using newCAST software (Visiopharm, Hørsholm, Denmark). Briefly, lungs were sampled, fixed in 4% buffered paraformaldehyde solution, and paraffin-embedded. Five-micrometer-thick sections were stained with hematoxylin and eosin (H&E) for lung structure evaluation. The total lung volume and its compartments, and volume densities were estimated by the Cavaliere principle. The density surface, the total surface area of the alveolar septa, and the arithmetic mean thickness were also assessed as described in Hsia et al. [44].

In addition, a semi-quantitative analysis of the inflammation was performed by an experienced pathologist to determine histopathological characteristics using the following scores: grade 0 (absent), 1 (discrete), 2 (mild), 3 (moderate), and 4 (intense) [45].

4.5. Molecular Analysis

Toll-like Receptor (TLR)-2, TLR4, MyD-88, and Foxp3 mRNA were quantified by real-time PCR using specific primers. All primer sequences are presented in Supplementary Table S2.

Total RNA of the frozen lungs was extracted with TRizol (Ambion, Life Technologies, Carlsbad, CA, USA), cDNA synthesis (SuperScript VILO cDNA Synthesis Kit, Invitrogen, Life Technologies, Carlsbad, CA, USA), and real-time PCR (Fast SYBR Green Master Mix, Applied Biosystems, Life Technologies, Carlsbad, CA, USA) were conducted according to the manufacturer’s protocols. The relative expression of the transcripts was calculated after normalization to the levels of the reference gene of the ribosomal protein L13A [46].

4.6. Immunohistochemically Inflammation Assessment

Lung tissue was immunostained using anti-IL-1β, anti-IL-4, anti-IL-5, anti-IL-6, anti-IL-10, anti-IL-17, and anti-TNF-α antibodies. The inflammatory cytokines were quantified in the lung parenchyma by measuring the proportional area (stained area/lung tissue area) in 15 HPFs per animal using the Image-Pro Plus 4.1 software (Media Cybernetics, Silver Spring, MD, USA). Furthermore, lung tissue sections were immunostained using anti-myeloperoxidase (MPO), anti-CD3, and anti-MAC2 antibodies. The immunostained cells were counted in 20 high power fields (HPFs) and the proportion of cells per area of lung tissue was calculated. The standardized dilutions of the antibodies and their commercial sources are presented in Supplementary Table S3.

4.7. Statistical Analysis

We used the SPSS 21 software (SPSS Inc/IBM, Chicago, IL, USA) for the statistical analyses and the GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA) for data visualization. Descriptive statistics were calculated for each variable and group. We performed ANOVA or the Kruskal–Wallis test, followed by Tukey or Bonferroni post hoc tests to compare the groups according to the normality of distribution, previously assessed by the Kolmogorov–Smirnov normality test. Furthermore, we performed a two-way analysis of variance (two-way ANOVA) to verify the influence of the LPS nebulization, PM$_{2.5}$ exposure, and their interaction on each variable. Statistical differences were assumed at the 5% significance level.

5. Conclusions

PM$_{2.5}$ is a heterogeneous mixture of organic and inorganic components and, even with all the findings highlighting its complexity and dynamic nature, its effects in the lung are not fully understood. Their ability to cause injury may vary with their size, physical and chemical characteristics, and source. Different characteristics of PM$_{2.5}$ may be relevant to different health effects. The animals with LPS-induced acute lung injury that were previously exposed to PM$_{2.5}$ showed a mixed inflammatory response, and our analysis shows that there is often an interaction between the LPS nebulization and PM$_{2.5}$ exposure,
modulating differently the inflammatory response, with a distinct pattern when compared with the LPS or the PM$_{2.5}$ exposure alone.

Further studies are required to explain the mechanisms of immune modulation caused by chronic exposure to PM$_{2.5}$ and how it could alter the onset, progression, and resolution of acute lung injury and the susceptibility to secondary respiratory infections.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms23073913/s1.

**Author Contributions:** Conceptualization, P.H.N.S., M.D. and L.F.F.d.S.; data curation, N.d.S.X.C. and S.R.; formal analysis, N.d.S.X.C., G.R.J., A.A.d.S.A., L.B., M.F.C., S.R. and M.M.V.; funding acquisition, P.H.N.S. and L.F.F.d.S.; investigation, N.d.S.X.C., G.R.J., A.A.d.S.A., L.B., M.F.C., S.R., M.M.V. and E.G.K.; methodology, N.d.S.X.C., P.H.N.S. and L.F.F.d.S.; project administration, L.F.F.d.S.; resources, E.G.K. and P.H.N.S.; supervision, M.D. and L.F.F.d.S.; validation, N.d.S.X.C., M.D. and L.F.F.d.S.; visualization, N.d.S.X.C. and L.B.; writing—original draft, N.d.S.X.C., M.D. and L.F.F.d.S.; writing—review and editing, N.d.S.X.C., M.D. and L.F.F.d.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Conselho Nacional de Desenvolvimento Científico e Tecnológico, Grant no #573813/2008-6 and Grant no #479679/2012-6 and by Fundação de Amparo à Pesquisa do Estado de São Paulo, Grant no #2008/57717-6 and Grant no #2012/23334-9.

**Institutional Review Board Statement:** The Institutional Review Board for Ethics on Animal Use of the University of São Paulo—School of Medicine approved all ethics aspects of this project (protocol no. 177/10 was approved on 6 November 2012), including animal manipulation and euthanasia.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information Files.

**Acknowledgments:** The author would like to thank Kely Cristina Soares Bispo and all the staff from the Histopathology Laboratory and Angela B. G. dos Santos for all the technical support. The authors also would like to thank Fundação de Amparo à Pesquisa do Estado de São Paulo and Conselho Nacional de Desenvolvimento Científico e Tecnológico for financial support.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**References**

1. Schraufnagel, D.E.; Balmes, J.R.; Cowl, C.T.; De Matteis, S.; Jung, S.H.; Mortimer, K.; Perez-Padilla, R.; Rice, M.B.; Riojas-Rodriguez, H.; Sood, A.; et al. Air Pollution and Noncommunicable Diseases: A Review by the Forum of International Respiratory Societies’ Environmental Committee, Part 1: The Damaging Effects of Air Pollution. *Chest* 2019, 155, 409–416. [CrossRef] [PubMed]

2. World Health Organization. WHO Global Air Quality Guidelines. Particulate Matter (PM2.5 and PM10), Ozone, Nitrogen Dioxide, Sulfur Dioxide, and Carbon Monoxide. Available online: https://www.who.int/publications/i/item/9789240034228?ua=1 (accessed on 27 November 2021).

3. Forbes, L.J.; Kapetanakis, V.; Rudnicka, A.R.; Cook, D.G.; Bush, T.; Stedman, J.R.; Whincup, P.H.; Strachan, D.P.; Anderson, H.R. Chronic exposure to outdoor air pollution and lung function in adults. *Thorax* 2009, 64, 657–663. [CrossRef]

4. Reilly, J.P.; Zhao, Z.; Shashaty, M.G.S.; Koyama, T.; Christie, J.D.; Lanken, P.N.; Wang, C.; Balmes, J.R.; Matthay, M.A.; Calfee, C.S.; et al. Low to Moderate Air Pollutant Exposure and Acute Respiratory Distress Syndrome after Severe Trauma. *Am. J. Respir. Crit. Care Med.* 2019, 199, 62–70. [CrossRef]

5. Manisalidis, I.; Stavropoulou, E.; Stavropoulos, A.; Bezirtzoglou, E. Environmental and Health Impacts of Air Pollution: A Review. *Front. Public Health* 2020, 8, 14. [CrossRef] [PubMed]

6. Arias-Pérez, R.D.; Taborda, N.A.; Gómez, D.M.; Narvaez, J.F.; Porras, J.; Hernandez, J.C. Inflammatory effects of particulate matter air pollution. *Environ. Sci. Pollut. Res.* 2020, 27, 42390–42404. [CrossRef] [PubMed]

7. Gałuszka, A.; Stec, M.; Węglarczyk, K.; Kluczewska, A.; Siedlar, M.; Baran, J. Transition Metal Containing Particulate Matter Promotes Th1 and Th17 Inflammatory Response by Monocyte Activation in Organic and Inorganic Compounds Dependent Manner. *Int. J. Environ. Res. Public Health* 2020, 17, 1227. [CrossRef]

8. Wang, X.; Quinn, P.J. Lipopolysaccharide: Biosynthetic pathway and structure modification. *Prog. Lipid Res.* 2010, 49, 97–107. [CrossRef]
9. Ebbensgaard, A.; Mordhorst, H.; Aæstrup, F.M.; Hansen, E.B. The Role of Outer Membrane Proteins and Lipopolysaccharides for the Sensitivity of Escherichia coli to Antimicrobial Peptides. Front. Microbiol. 2018, 9, 2153. [CrossRef]

10. Klein, G.; Müller-Loennies, S.; Lindner, B.; Kobylak, N.; Brade, H.; Raina, S. Molecular and structural basis of inner core lipopolysaccharide alterations in Escherichia coli: Incorporation of glucuronic acid and phosphoethanolamine in the heptose region. J. Biol. Chem. 2013, 288, 8111–8127. [CrossRef]

11. Seeley, J.J.; Ghosh, S. Molecular mechanisms of innate memory and tolerance to LPS. J. Leukoc. Biol. 2017, 101, 107–119. [CrossRef]

12. Yanagisawa, R.; Takano, H.; Inoue, K.; Ichinose, T.; Sadakane, K.; Yoshino, S.; Yamaki, K.; Kumagai, Y.; Uchiyama, K.; Yoshikawa, T.; et al. Enhancement of acute lung injury related to bacterial endotoxin by components of diesel exhaust particles. Thorax 2003, 58, 605–612. [CrossRef][PubMed]

13. Takano, H.; Yanagisawa, R.; Ichinose, T.; Sadakane, K.; Yoshino, S.; Yoshikawa, T.; Morita, M. Diesel exhaust particles enhance lung injury related to bacterial endotoxin through expression of proinflammatory cytokines, chemokines, and intercellular adhesion molecule-1. Am. J. Respir. Crit. Care Med. 2002, 165, 1329–1335. [CrossRef]

14. Kim, D.I.; Song, M.K.; Lee, K. Diesel Exhaust Particles Enhances Susceptibility of LPS-Induced Acute Lung Injury through Upregulation of the IL-17 Cytokine-Derived TGF-β1/Collagen I Expression and Activation of NLRP3 Inflammasome Signaling in Mice. Biomolecules 2021, 11, 67. [CrossRef]

15. Andrade, M.D.; de Miranda, R.M.; Fornaro, A.; Kerr, A.; Oyama, B.; de Andre, P.A.; Saldiva, P. Vehicle emissions and PM(2.5) mass concentrations in six Brazilian cities. Air Qual. Atmos. Health 2012, 5, 79–88. [CrossRef]

16. de Miranda, R.M.; de Fatima Andrade, M.; Fornaro, A.; Astolfo, R.; de Andre, P.A.; Saldiva, P. Urban air pollution: A representative survey of PM(2.5) mass concentrations in six Brazilian cities. Air Qual. Atmos. Health 2012, 5, 63–77. [CrossRef]

17. de Barros Mendes Lopes, T.; Groth, E.E.; Veras, M.; Furuya, T.K.; de Souza Xavier Costa, N.; Ribeiro Júnior, G.; Lopes, F.D.; de Almeida, E.M.; Cardoso, W.V.; Saldiva, P.H.N.; et al. Pre- and postnatal exposure of mice to concentrated urban PM2.5 decreases the number of alveoli and leads to altered lung function at an early stage of life. Environ. Pollut. 2018, 241, 511–520. [CrossRef]

18. Yoshizaki, K.; Fuziwa, C.S.; Brito, J.M.; Santos, T.M.N.; Correia, A.T.; Amato-Lourenco, L.F.; Vasconcellos, P.; Silva, L.F.; Bentanini, M.M.; et al. The effects of urban particulate matter on the nasal epithelium by gender: An experimental study in mice. Environ. Pollut. 2016, 213, 359–369. [CrossRef]

19. de Souza Xavier Costa, N.; Ribeiro Júnior, G.; Dos Santos Alemany, A.A.; Belotti, L.; Schalch, A.S.; Cavalcante, M.F.; Ribeiro, S.; Veras, M.M.; Kallás, E.G.; Saldiva, P.H.N.; et al. Air pollution impairs recovery and tissue remodeling in a murine model of acute lung injury. Sci. Rep. 2020, 10, 15314. [CrossRef]

20. Matute-Bello, G.; Frevert, C.W.; Martin, T.R. Animal models of acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 295, L379–L399. [CrossRef]

21. Park, B.; Lee, J.O. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp. Mol. Med. 2013, 45, e66. [CrossRef]

22. Liu, J.; Chen, X.; Dou, M.; He, H.; Ju, M.; Ji, S.; Zhou, J.; Chen, C.; Zhang, D.; Miao, C.; et al. Particulate matter disrupts airway epithelial barrier via oxidative stress to promote Pseudomonas aeruginosa infection. J. Thorac. Dis. 2019, 11, 2617–2627. [CrossRef]

23. Sahuquillo-Arce, J.M.; Ibáñez-Martínez, E.; Hernández-Cabezás, A.; Ruiz-Gaitán, A.; Falomir-Salcedo, P.; Menéndez, R.; López-Hontangas, J.L. Influence of environmental conditions and pollution on the incidence of Streptococcus pneumoniae infections. ERJ Open Res. 2017, 3, 00014–02017. [CrossRef]

24. Lin, Y.J.; Lin, H.C.; Yang, Y.F.; Chen, C.Y.; Ling, M.P.; Chen, S.C.; Chen, W.Y.; You, S.H.; Lu, T.H.; Liao, C.M. Association Between Lipopolysaccharide Alterations in Escherichia coli and the Sensitivity of Antimicrobial Peptides. Front. Microbiol. 2018, 9, 2153. [CrossRef]

25. Renwick, L.C.; Brown, D.; Clouter, A.; Donaldson, K. Increased inflammation and altered macrophage chemotactic responses caused by two ultrafine particle types. Occup. Environ. Med. 2004, 61, 442–447. [CrossRef]

26. Becker, S.; Soukup, J.M.; Sioutas, C.; Cassee, F.R. Response of human alveolar macrophages to ultrafine, fine, and coarse urban air pollution particles. Exp. Lung Res. 2003, 29, 29–44. [CrossRef]

27. Miyata, R.; van Eeden, S.F. The innate and adaptive immune response induced by alveolar macrophages exposed to ambient particulate matter. Toxicol. Appl. Pharmacol. 2011, 257, 209–226. [CrossRef]

28. Yang, J.; Kim, E.K.; Park, H.J.; McDowell, A.; Kim, Y.K. The impact of bacteria-derived ultrafine dust particles on pulmonary diseases. Exp. Mol. Med. 2020, 52, 338–347. [CrossRef]

29. Gurczynski, S.J.; Moore, B.B. IL-17 in the lung: The good, the bad, and the ugly. Am. J. Physiol. Lung Cell Mol. Physiol. 2018, 314, L6–L16. [CrossRef][PubMed]

30. Pagani, I.G.; Santos, J.M.B.; Foster, R.; Rossi, M.; Luna Junior, L.A.; Katekaru, C.M.; de Sá, M.C.; Jonckheere, A.C.; Almeida, F.M.; Amaral, J.B.; et al. The Effect of Particulate Matter Exposure on the Inflammatory Airway Response of Street Runners and Sedentary People. Atmosphere 2020, 11, 43. [CrossRef]

31. van Voooris, M.; Knopp, S.; Julliard, W.; Fechner, J.H.; Zhang, X.; Schauer, J.J.; Mezrich, J.D. Exposure to atmospheric particulate matter enhances Th17 polarization through the aryl hydrocarbon receptor. PLoS ONE 2013, 8, e82545. [CrossRef][PubMed]

32. Chu, S.; Zhong, X.; Zhang, J.; Lao, Q.; He, Z.; Bai, J. The expression of Foxp3 and ROR gamma t in lung tissues from normal smokers and chronic obstructive pulmonary disease patients. Int. Immunopharmacol. 2011, 11, 1780–1788. [CrossRef][PubMed]
34. Nadeau, K.; McDonald-Hyman, C.; Noth, E.M.; Pratt, B.; Hammond, S.K.; Balmes, J.; Tager, I. Ambient air pollution impairs regulatory T-cell function in asthma. *J. Allergy Clin. Immunol.* **2010**, *126*, 845–852. [CrossRef]  
35. Nomura, F.; Akashi, S.; Sakao, Y.; Sato, S.; Kawai, T.; Matsumoto, M.; Nakanishi, K.; Kimoto, M.; Miyake, K.; Takeda, K.; et al. Cutting edge: Endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. *J. Immunol.* **2000**, *164*, 3476–3479. [CrossRef] [PubMed]  
36. Guzmán-Beltrán, S.; Torres, M.; Arellano, M.; Juárez, E. Human macrophages chronically exposed to LPS can be reactivated by stimulation with MDP to acquire an antimicrobial phenotype. *Cell Immunol.* **2017**, *315*, 45–55. [CrossRef] [PubMed]  
37. Croft, D.P.; Burton, D.S.; Nagel, D.J.; Bhattacharya, S.; Falsey, A.R.; Georas, S.N.; Hopke, P.K.; Johnston, C.J.; Kottmann, R.M.; Litonjua, A.A.; et al. The effect of air pollution on the transcriptomics of the immune response to respiratory infection. *Sci. Rep.* **2021**, *11*, 19436. [CrossRef] [PubMed]  
38. Andrade, M.F.; Kumar, P.; Freitas, E.D.; Ynoue, R.Y.; Martins, J.; Martins, L.D.; Nogueira, T.; Perez-Martínez, P.; Miranda, R.M.; Albuquerque, T.; et al. Air quality in the megacity of São Paulo: Evolution over the last 30 years and future perspectives. *Atmos. Environ.* **2017**, *159*, 66–82. [CrossRef]  
39. CETESB. Qualidade do ar no Estado de São Paulo 2020. Available online: https://cetesb.sp.gov.br/ar/wp-content/uploads/sites/28/2021/05/Relatorio-de-Qualidade-do-Ar-no-Estado-de-Sao-Paulo-2020.pdf (accessed on 27 November 2021).  
40. Phalen, R.F.; Oldham, M.J.; Wolff, R.K. The relevance of animal models for aerosol studies. *J. Aerosol Med. Pulm. Drug Deliv.* **2008**, *21*, 113–124. [CrossRef]  
41. Mestas, J.; Hughes, C.C. Of mice and not men: Differences between mouse and human immunology. *J. Immunol.* **2004**, *172*, 2731–2741. [CrossRef]  
42. Sioutas, C.; Koutrakis, P.; Burton, R.M. A technique to expose animals to concentrated fine ambient aerosols. *Environ. Health Perspect.* **1995**, *103*, 172–177. [CrossRef]  
43. de Souza Xavier Costa, N.; Ribeiro Júnior, G.; Dos Santos Alemany, A.A.; Belotti, L.; Zati, D.H.; Frota Cavalcante, M.; Matera Veras, M.; Ribeiro, S.; Kallás, E.G.; Nascimento Saldiva, P.H.; et al. Early and late pulmonary effects of nebulized LPS in mice: An acute lung injury model. *PLoS ONE* **2017**, *12*, e0185474. [CrossRef] [PubMed]  
44. Hsia, C.C.; Hyde, D.M.; Ochs, M.; Weibel, E.R. An official research policy statement of the American Thoracic Society/European Respiratory Society: Standards for quantitative assessment of lung structure. *Am. J. Respir. Crit. Care Med.* **2010**, *181*, 394–418. [CrossRef] [PubMed]  
45. Meyerholz, D.K.; Sieren, J.C.; Beck, A.P.; Flaherty, H.A. Approaches to evaluate lung inflammation in translational research. *Vet. Pathol.* **2018**, *55*, 42–52. [CrossRef] [PubMed]  
46. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* **2001**, *25*, 402–408. [CrossRef] [PubMed]